Advertisement

PharmacoEconomics

, Volume 15, Issue 4, pp 339–355 | Cite as

Methodological Hurdles in Conducting Pharmacoeconomic Analyses

  • J. Douglas Rizzo
  • Neil R. Powe
Review Article Methodological Hurdles in Pharmacoeconomic Analysis

Abstract

As total healthcare spending increases throughout the world, greater emphasis is being placed on research which demonstrates value for medical interventions, including new and existing pharmaceuticals. Pharmacoeconomic evaluations can assist manufacturers, insurers, clinicians, governmental agencies, policy-makers and consumers to make informed, appropriate decisions about adoption and application of new medications. Because of the far-reaching implications of this research, it is important that researchers adequately address methodological challenges.

In this article, we describe the uses of results of pharmacoeconomic trials, identify and discuss various study designs and methods for gathering nonclinical outcome data which may differ significantly from clinical outcome data, and consider the importance and difficulty of incorporating the patients’ experience into such trials. Researchers in this area must give specific consideration to sample size estimation for economic outcomes, and carefully handle time issues including duration of observation for complications and discounting of future health and financial consequences. Costs from different perspectives associated with resource use should be assembled in a standard fashion. Use of charges which may not be standardised across geographical or organisational boundaries are discouraged. Inclusion of appropriate health-related quality-of-life (HR-QOL) and utility instruments is increasingly important, but controversy over the best methods still exists. While there is little question of the importance of pharmacoeconomic evaluations, they are expensive. Well designed and executed pharmacoeconomic trials can justify this expense by helping decision-makers understand which treatments have value.

Keywords

Adis International Limited Ondansetron Pharmacoeconomic Analysis Pharmacoeconomic Evaluation Primary Data Analysis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Organization for Economic Cooperation Development (OECD). OECD Health Data 97. Paris: OECD, 1997Google Scholar
  2. 2.
    Canadian Coordinating Office for Health Technology Assessment (CCOHTA). Guidelines for economic evaluation of pharmaceuticals. Ottawa (ON): CCOHTA, 1994Google Scholar
  3. 3.
    Menon D, Schubert F, Torrance GW. Canadas new guidelines for the economic evaluation of pharmaceuticals. Med Care 1996; 34 (12 Suppl. S): DS77–86Google Scholar
  4. 4.
    Commonwealth Department of Health, Local Government. Background document: on the use of economic analysis as a basis for inclusion of pharmaceutical products on the Pharmaceutical Benefits Scheme. Canberra: Australian Government Publishing Service, 1993Google Scholar
  5. 5.
    Evans D, Freund D, Dittus R, et al. The use of economic analysis as a basis for inclusion of pharmaceutical products on the pharmaceutical benefits scheme. Canberra: Department Health, Housing, Community Service, 1990Google Scholar
  6. 6.
    Powe NR, Griffiths RI. The clinical-economic trial: promise, problems, and challenges. Control Clin Trials 1995; 16: 377–94PubMedCrossRefGoogle Scholar
  7. 7.
    United States Congress and Office of Technology Assessment. Pharmaceutical research and development: costs, risks and rewards. Washington, DC: Government Printing Office, 1993Google Scholar
  8. 8.
    Drummond M, Jonsson B, Rutten F. The role of economic evaluation in the pricing and reimbursement of medicines. Health Policy 1997; 40 (3): 199–215PubMedCrossRefGoogle Scholar
  9. 9.
    Luce BR, Lyles CA, Rentz AM. The view from managed care pharmacy. Health Aff 1996; 15 (4): 168–76CrossRefGoogle Scholar
  10. 10.
    Steiner CA, Powe NR, Anderson GF, et al. The review process and information used by health care plans in the United States to evaluate new medical technology. J Gen Intern Med 1996; 11294–302Google Scholar
  11. 11.
    American Society of Clinical Oncology. American Society of Clinical Oncology recommendations for ht euse of hematopoietic colony stimulating factors: evidence-based clinical practice guidelines. J Clin Oncol 1994; 12: 2471–508Google Scholar
  12. 12.
    American Society of Clinical Oncology. Update of recommendations for the use of hematopoietic colony stimulating factors: evidence-based clinical practice guidelines. J Clin Oncol 1996; 14 (6): 1957–60Google Scholar
  13. 13.
    Iglehart JK. The American health care system: expenditures. N Engl J Med 1999; 340: 70–6PubMedCrossRefGoogle Scholar
  14. 14.
    Wennberg JE, Gittelsohn A. Small area variations in health care delivery: a population-based health information system can guide planning and regulatory decision-making. Science 1973; 182: 1102–8PubMedCrossRefGoogle Scholar
  15. 15.
    Wennberg JE, Gittelsohn A. Health care delivery in Maine. I: patterns of use of common surgical procedures. J Maine Med Assoc 1975; 66: 123–30PubMedGoogle Scholar
  16. 16.
    Wennberg JE, Gittelsohn A. Health care delivery in Maine. II: conditions explaining admission to hospital. J Maine Med Assoc 1975; 66: 255–61PubMedGoogle Scholar
  17. 17.
    Wennberg JE, Gittelsohn A. Health care delivery in Maine. III: evaluating the performance of hospitals. J Maine Med Assoc 1975; 66: 298–306PubMedGoogle Scholar
  18. 18.
    Wennberg JE, Gittelsohn A. Variations in medical care among small areas. Sci Am 1982; 246 (4): 120–34PubMedCrossRefGoogle Scholar
  19. 19.
    Wennberg JE, Cooper MM, editors. The Dartmouth Atlas of Health Care 1998. Chicago (IL): American Hospital Publishing, Inc., 1998Google Scholar
  20. 20.
    National Institutes of Health Consensus Development Panel. National Institutes of Health Consensus Development Conference Statement: breast cancer screening for women ages 40-49, January 21-23, 1997. Journal Natl Cancer Inst 1997; 89 (14): 1015–26CrossRefGoogle Scholar
  21. 21.
    Field MJ, Lohr KN, editors. Clinical practice guidelines: directions for a new program. Washington, DC: National Academy Press, 1990Google Scholar
  22. 22.
    US Preventive Services Task Force. Guide to clinical preventive services. 2nd ed. In: Cost-effectiveness and clinical preventive services. Baltimore (MD): Williams & Wilkins, 1996: 1xxxv–ciiGoogle Scholar
  23. 23.
    Medicare Program: criteria and procedures for making medical services coverage decisions that relate to health care technology. Fed Regist 1989; 54: 4304Google Scholar
  24. 24.
    State of Maryland Health Care Access and Cost Commission. Comparing the quality of Maryland HMO’s: a guide for consumers. Baltimore (MD): Maryland Health Care Access and Cost Commission, 1997Google Scholar
  25. 25.
    Assessing medical technologies: Institute of Medicine Committee for Evaluating Medical Technologies in Clinical Use. Washington, DC: National Academy Press, 1985Google Scholar
  26. 26.
    Schulman KA, Llana T, Yabroff KR. Economic assessment within the clinical development program. Med Care 1996; 34 (12 Suppl.): DS89–95Google Scholar
  27. 27.
    Iezonni LI. Assessing quality using administrative databases. Ann Intern Med 1997; 127: 666–74Google Scholar
  28. 28.
    Whittle J. Large administrative databases in U.S. Congress, Office of Technology Assessment: tools for evaluation health technologies. Washington, DC: US Government Printing Office, 1995. Report no.: BP-H-142Google Scholar
  29. 29.
    Weinstein MC, Fineberg HV, Frazier AS, et al. Clinical decision analysis. Philadelphia (PA): WB Saunders, 1980Google Scholar
  30. 30.
    Glick H, Schulman KA, Kinosian B. Decision-analytic modelling: some uses in the evaluation of new pharmaceuticals. Drug Inf J 1994; 28: 691CrossRefGoogle Scholar
  31. 31.
    Zbrozek AS, Cantor SB, Cardenas MP, et al. Pharmacoeconomic analysis of ondansetron versus metoclopramide for cisplatin-induced nausea and vomiting. Am J Hosp Pharm 1994; 51 (12): 1555–63PubMedGoogle Scholar
  32. 32.
    Zhou X, Melfi CA, Hiui SL. Methods for comparison of cost data. Ann Intern Med 1997; 127: 752–6PubMedGoogle Scholar
  33. 33.
    Glasziou PP, Simes RJ, Hall J, et al. Design of a cost-effectiveness study within a randomized trial – the LIPID trial for secondary prevention of IHD. Control Clin Trials 1997; 18 (5): 464–76PubMedCrossRefGoogle Scholar
  34. 34.
    Mark DB, Hlatky MA, Califf RM, et al. Cost-effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction. N Engl J Med 1995; 332 (21): 1418–24PubMedCrossRefGoogle Scholar
  35. 35.
    Eisenberg J. Clinical economics: a guide to the economic analysis of clinical practices. JAMA 1989; 262: 2879–86PubMedCrossRefGoogle Scholar
  36. 36.
    Weinstein MC, Stason WB. Foundations of cost-effectiveness analysis for health and medical practices. N Engl J Med 1977; 296 (13): 716–21PubMedCrossRefGoogle Scholar
  37. 37.
    Gold MR, Siegel JE, Russell LB, et al., editors. Cost-effectiveness in health and medicine. New York (NY): Oxford University Press, 1996Google Scholar
  38. 38.
    Kennedy BJ. Excessive test costs in clinical research protocols. J Cancer Educ 1991; 6 (2): 93–7PubMedCrossRefGoogle Scholar
  39. 39.
    Bennett CL, George SL, Vose JM, et al. Granulocyte-macrophage colony-stimulating factor as adjunct therapy in relapsed lymphoid malignancy: implications for economic analyses of phase III clinical trials. Stem Cells 1995; 13 (4): 414–20PubMedCrossRefGoogle Scholar
  40. 40.
    Davidoff AJ, Powe NR. The role of perspective in defining economic measures for the evaluation of medical technology. Int J Technol Assess Health Care 1996; 12 (1): 9–21PubMedCrossRefGoogle Scholar
  41. 41.
    Udvarhelyi S, Colditz GA, Rai A, et al. Cost-effectiveness and cost-benefit analyses in the medical literature. Ann Intern Med 1992; 116: 238–44PubMedGoogle Scholar
  42. 42.
    Rizzo J, Vogelsang G, Krumm S, et al. Outpatient BMT for hematologic malignancies: cost-saving or cost-shifting? [abstract]. Blood 1997; 90 (10 Suppl. 1): 417aGoogle Scholar
  43. 43.
    Fryback DG, Dasbach EJ, Klein R, et al. The Beaver Dam Health Outcomes Study: initial catalog of health-state quality factors. Med Decis Making 1993; 13 (2): 89–102PubMedCrossRefGoogle Scholar
  44. 44.
    Gold MR, Franks P, McCoy KI, et al. Toward consistency in cost utility analyses: using national measures to create condition- specific values. Med Care 1998; 36: 775–7CrossRefGoogle Scholar
  45. 45.
    EuroQol Group. EuroQol: a new facility for the measurement of health related quality of life. Health Policy 1990; 16: 199–208CrossRefGoogle Scholar
  46. 46.
    Kaplan RM, Bush JW, Bern CC. Health status: types of validity and the index of well-being. Health Serv Res 1976; 11: 478–527PubMedGoogle Scholar
  47. 47.
    Ware JE, Sherbourne DC. The MOS 36-item short-form health survey. Med Care 1992; 30: 473–83PubMedCrossRefGoogle Scholar
  48. 48.
    Cella DF, Tulsky DS, Gray G, et al. The Functional Assessment of Cancer Therapy Scale: development and validation of the general measure. J Clin Oncol 1993; 11 (3): 570–9PubMedGoogle Scholar
  49. 49.
    O’Leary JF, Fairclough DL, Jankowski MK, et al. Comparison of time-tradeoff utilities and rating scale values of cancer patients and their relatives: evidence for a possible plateau relationship. Med Decis Making 1995; 15: 132–7PubMedCrossRefGoogle Scholar
  50. 50.
    Fink N, Bass E, Wills S, et al. Quality of life (preferences) for current health status in incident hemodialysis and peritoneal dialysis patients. J Am Soc Nephrol 1997; 8: 137AGoogle Scholar
  51. 51.
    Bennett CL, Westerman IL. Economic analysis during phase III clinical trials: who, what, when, where, and why?. Oncology 1995; 9 (11 Suppl.): 169–75PubMedGoogle Scholar
  52. 52.
    Zhou XH, Melfi CA, Hui SL. Methods for comparison of cost data. Ann Intern Med 1997; 127: 752–6PubMedGoogle Scholar
  53. 53.
    Zhou XH, Gao S, Hui SL. Methods for comparing the means of two independent log-normal samples. Biometrics 1998; 53: 1129–35CrossRefGoogle Scholar
  54. 54.
    Shine KI. Some imperatives for clinical research. JAMA 1997; 278 (3): 245–6PubMedCrossRefGoogle Scholar
  55. 55.
    Stelfox HT, Chua G, O’Rourke K, et al. Conflict of interest in the debate over calcium-channel antagonists. N Engl J Med 1998; 338 (2): 101–6PubMedCrossRefGoogle Scholar
  56. 56.
    Hillman AL, Eisenberg JM, Pauly MV, et al. Avoiding bias in the conduct and reporting of cost-effectiveness research sponsored by pharmaceutical companies. N Engl J Med 1991; 324 (19): 1362–5PubMedCrossRefGoogle Scholar
  57. 57.
    Kassirer JP, Angell M. The journal’s policy on cost-effectiveness analysis. N Engl J Med 1994; 331: 669–70PubMedCrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG 1999

Authors and Affiliations

  1. 1.International Bone Marrow Transplant Registry/Autologous Blood and Marrow Transplant Registry, Medical College of WisconsinMilwaukeeUSA
  2. 2.Robert Wood Johnson Clinical Scholars Program, Johns Hopkins University School of MedicineBaltimoreUSA
  3. 3.Welch Center for Prevention, Epidemiology and Clinical ResearchJohns Hopkins University School of MedicineBaltimoreUSA
  4. 4.Department of MedicineEpidemiology and Health Policy and Management, Johns Hopkins UniversityBaltimoreUSA

Personalised recommendations